Show simple item record

dc.contributor.authorMinnee, H
dc.contributor.authorRack, JGM
dc.contributor.authorvan der Marel, GA
dc.contributor.authorOverkleeft, HS
dc.contributor.authorCodée, JDC
dc.contributor.authorAhel, I
dc.contributor.authorFilippov, D
dc.date.accessioned2023-10-31T14:27:28Z
dc.date.issued2023-10-30
dc.date.updated2023-10-31T12:01:24Z
dc.description.abstractThe transfer of an adenosine diphosphate (ADP) ribose moiety to a nucleophilic side chain by consumption of nicotinamide adenine dinucleotide is referred to as ADP-ribosylation, which allows for the spatiotemporal regulation of vital processes such as apoptosis and DNA repair. Recent mass-spectrometry based analyses of the ‘ADP-ribosylome’ have identified histidine as ADP-ribose acceptor site. In order to study this modification, a fully synthetic strategy towards α-configured N(τ)- and N(π)-ADP-ribosylated histidine-containing peptides has been developed. Ribofuranosylated histidine building blocks were obtained via Mukaiyama-type glycosylation and the building blocks were integrated into an ADP-ribosylome derived peptide sequence using fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase peptide synthesis. On-resin installation of the ADP moiety was achieved using phosphoramidite chemistry, and global deprotection provided the desired ADP-ribosylated oligopeptides. The stability under various chemical conditions and resistance against (ADP-ribosyl) hydrolase-mediated degradation has been investigated to reveal that the constructs are stable under various chemical conditions and non-degradable by any of the known ADP-ribosylhydrolases.en_GB
dc.description.sponsorshipMedical Research Council (MRC)en_GB
dc.description.sponsorshipNational Institute for Health and Care Research (NIHR)en_GB
dc.description.sponsorshipWellcome Trusten_GB
dc.description.sponsorshipBiotechnology and Biological Sciences Research Council (BBSRC)en_GB
dc.description.sponsorshipCancer Research UKen_GB
dc.description.sponsorshipOvarian Cancer Research Allianceen_GB
dc.identifier.citationArticle e202313317en_GB
dc.identifier.doihttps://doi.org/10.1002/ange.202313317
dc.identifier.grantnumberMR/N006364/2en_GB
dc.identifier.grantnumberMR/V033417/1en_GB
dc.identifier.grantnumberMR/X007472/1en_GB
dc.identifier.grantnumber210634en_GB
dc.identifier.grantnumber223107en_GB
dc.identifier.grantnumberBB/R007195/1en_GB
dc.identifier.grantnumberBB/W016613/1en_GB
dc.identifier.grantnumberC35050/A22284en_GB
dc.identifier.grantnumber813369en_GB
dc.identifier.urihttp://hdl.handle.net/10871/134369
dc.identifierORCID: 0000-0001-8341-6439 (Rack, Johannes GM)
dc.language.isoenen_GB
dc.publisherWiley / Gesellschaft Deutscher Chemikeren_GB
dc.rights.embargoreasonUnder embargo until 30 October 2024 in compliance with publisher policy
dc.rights© 2023 Wileyen_GB
dc.subjectADP-ribosylationen_GB
dc.subjectGlycosylationen_GB
dc.subjectHistidineen_GB
dc.subjectPeptidesen_GB
dc.subjectSolid-phase synthesisen_GB
dc.titleSolid‐Phase Synthesis and Biological Evaluation of Peptides ADP‐ribosylated at Histidineen_GB
dc.typeArticleen_GB
dc.date.available2023-10-31T14:27:28Z
dc.identifier.issn0044-8249
dc.descriptionThis is the author accepted manuscript. The final version is available from Wiley via the DOI in this recorden_GB
dc.identifier.eissn1521-3757
dc.identifier.journalAngewandte Chemieen_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2023-10-30
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2023-10-31T14:22:49Z
refterms.versionFCDAM
refterms.panelAen_GB
refterms.dateFirstOnline2023-10-30


Files in this item

This item appears in the following Collection(s)

Show simple item record